WALGREEN COMPANY for WALGREEN COMPANY
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
S. 336 and H.R. 684 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBBIE GARZA | — |
| ALETHIA JACKSON | — |
| EDWARD KALETA | — |
Health Issues HCR
S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBBIE GARZA | — |
| ALETHIA JACKSON | — |
| EDWARD KALETA | — |
Medicare/Medicaid MMM
S. 867 - the "Medicare Prescription Drug Program Integrity and Transparency Act," a bill to amend title XVIII of the Social Security Act to provide for pharmacy benefits manager standards under the Medicare prescription drug program, to establish basic audit standards of pharmacies, to further transparency of payment methodology to pharmacies, and to provide for recoupment returns to Medicare.S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. Issues related to related to pharmacists recognized as health care providers federally. No specific legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBBIE GARZA | — |
| ALETHIA JACKSON | — |
| EDWARD KALETA | — |
Consumer Issues/Safety/Products CSP
S. 957 - the "Drug Supply Chain Security Act," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain.H.R. 1919 - the "Safeguarding America's Pharmaceuticals Act of 2013," a bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the pharmaceutical distribution supply chain, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBBIE GARZA | — |
| ALETHIA JACKSON | — |
| EDWARD KALETA | — |
Pharmacy PHA
S. 959 - the "Pharmaceutical Compounding Quality and Accountability Act," all provisions regarding clarifying the oversight of pharmaceutical compounding by distinguishing between traditional comounding and compounding manufacturers and by establishing responsibilities of state and federal authorities.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBBIE GARZA | — |
| ALETHIA JACKSON | — |
| EDWARD KALETA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.